September 7, 2010 — Guidelines have been updated for use of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults, according to a report in the September 3 issue of MMWR. Morbidity and ...

The FDA has approved Capvaxive for the prevention of pneumococcal disease in at-risk children and adolescents.

Give the 13-valent pneumococcal conjugate vaccine to senior patients Give the 13-valent pneumococcal conjugate vaccine along with the 23-valent pneumococcal polysaccharide vaccine to all patients aged ...

The Advisory Committee on Immunization Practices (ACIP) has revised its interval recommendations for the pneumococcal polysaccharide vaccine (PPSV23) and pneumococcal conjugate vaccine (PCV13) in ...

Please provide your email address to receive an email when new articles are posted on . Researchers compared the 21-valent vaccine to a combination of a 15-valent and 23-valent vaccines. Fewer adverse ...

Please provide your email address to receive an email when new articles are posted on . Although vaccines have reduced the burden of pneumococcal disease, pneumonia due to Streptococcus pneumoniae and ...

Merck & Co. Inc. (NYSE:MRK) on Thursday released results from the Phase 3 STRIDE-13 trial evaluating Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) at the European Society of Clinical ...

(HealthDay)—A new policy has simplified the Advisory Committee on Immunization Practices (ACIP) pneumococcal vaccination recommendations; the updated recommendations are published in the Jan. 28 issue ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive data from multiple Phase 3 studies evaluating V116, the company’s ...